Sugimura Tetsu, Ito Yuhei, Tananari Yoshifumi, Ozaki Yukiko, Maeno Yasuki, Yamaoka Toshihiko, Kudo Yoshiyuki
Sugimura Children's Medical Clinic, Chikugo, Japan.
Vaccine. 2008 May 23;26(22):2700-5. doi: 10.1016/j.vaccine.2008.03.016. Epub 2008 Mar 31.
Antibody response to influenza vaccine is limited in early. Infants have poorer hemagglutination-inhibiting antibody responses than 12-month-old. Intradermal administration reportedly elicited immune responses similar to or better than a standard intramuscular dose. We hypothesized that intradermal injection could achieve a better response in infants than subcutaneous injection.
We randomized 34 healthy infants 6-12 months old to either intradermal immunization (0.1 ml of trivalent influenza vaccine containing at least 3 microg of hemagglutinin antigen per strain) or subcutaneous immunization (also 0.1 ml). Changes in hemagglutination inhibition titer were compared using Mann-Whitney U-test, changes in positivity rate, seroconversion, and seroprotection. Local and systemic adverse events were assessed.
All 32 infants received both injections. Antibody titers on days at 42 after intradermal injection were significantly greater than subcutaneous injection (P=0.032 in A/New Caledonia (H1N1), 0.019 in A New York (H3N2) and 0.044 in B/Shanghai. Positive titers for A New York (H3N2) were attained significantly more often after intradermal (73.3%) than subcutaneous injection (23.5%) on day 28, and significantly more often 42 days after intradermal injection (93.3% for A/New Caledonia (H1N1) and 73.3% for B/Shanghai) than after subcutaneous injection. Positive rates for other stains were similar between groups on days 28 and 42. Seroconversion rates were similar between groups. Seroprotection on day 42 for A New York (H3N2) was significantly greater in the intradermal (86.7%) than in the subcutaneous group (35.3%). Seroprotection rates for other stains were similar.
Intradermal administration to infants of two doses of influenza vaccine was more immunogenic than subcutaneous injection. Seroconversion and seroprotection rates remained insufficient. Further study of route, quantity, and frequency are needed to improve of responses in infants.
流感疫苗早期的抗体反应有限。婴儿的血凝抑制抗体反应比12个月大的儿童差。据报道,皮内给药引发的免疫反应与标准肌内剂量相似或更好。我们假设皮内注射对婴儿的反应比皮下注射更好。
我们将34名6至12个月大的健康婴儿随机分为皮内免疫组(0.1毫升三价流感疫苗,每株至少含3微克血凝素抗原)或皮下免疫组(也是0.1毫升)。使用曼-惠特尼U检验比较血凝抑制滴度的变化、阳性率、血清转化和血清保护的变化。评估局部和全身不良事件。
所有32名婴儿都接受了两种注射。皮内注射后42天的抗体滴度显著高于皮下注射(A/新喀里多尼亚(H1N1)中P = 0.032,A/纽约(H3N2)中P = 0.019,B/上海中P = 0.044)。在第28天,皮内注射后A/纽约(H3N2)的阳性滴度显著高于皮下注射(73.3%比23.5%),在皮内注射后42天也显著高于皮下注射(A/新喀里多尼亚(H1N1)为93.3%,B/上海为73.3%)。在第28天和42天,其他毒株的阳性率在两组之间相似。血清转化率在两组之间相似。在第42天,A/纽约(H3N2)的皮内血清保护率(86.7%)显著高于皮下组(35.3%)。其他毒株的血清保护率相似。
对婴儿皮内注射两剂流感疫苗比皮下注射更具免疫原性。血清转化和血清保护率仍然不足。需要进一步研究给药途径、剂量和频率以改善婴儿的反应。